Analysis

Moleculin Biotech, Inc. (MBRX) Stock Analysis

Moleculin Biotech, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to MBRX.

websiteMBRX/analysis/MBRX

Moleculin Biotech, Inc.

Moleculin Biotech, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to MBRX.

Stock profile

Ticker

MBRX

Asset type

Stock

Market cap

$15.4M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Moleculin Biotech, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • MBRX primary listing
  • 0K2H
  • MOL0
  • A41SET

Latest Moleculin Biotech, Inc. news

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Convent...

Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances HOUSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Molecu...

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annam...

HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safet...

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026...

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of careFirst 45-subject data unblinding expected...

Research sections

Valuation

Review valuation context for Moleculin Biotech, Inc..

Future growth

Review future growth context for Moleculin Biotech, Inc..

Past performance

Review past performance context for Moleculin Biotech, Inc..

Financial health

Review financial health context for Moleculin Biotech, Inc..

Dividend

Review dividend context for Moleculin Biotech, Inc..

Management

Review management context for Moleculin Biotech, Inc..

Ownership

Review ownership context for Moleculin Biotech, Inc..

Other information

Review other information context for Moleculin Biotech, Inc..

Community

Review community context for Moleculin Biotech, Inc..